Bone mineral densities in individuals with Gilbert's syndrome: A cross-sectional, case-control pilot study

Canadian Journal of Gastroenterology

Volumn 23, Issue 6, 2009, Pages 431-436

  Minuk, G Y ^a   Greenberg, R ^a   Uhanova, J ^a   Hawkins, K ^a   Leslie, W D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bone fractures; Cholestasis; Chronic liver disease; Gilbert's syndrome; Hyperbilirubinemia; Osteoblasts; Osteopenia; Osteoporosis; Unconjugated bilirubin

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; AGE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; BONE DENSITY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; FEMALE; FEMUR NECK; GILBERT DISEASE; HIP; HORMONE BLOOD LEVEL; HUMAN; MALE; MENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SPINE;

EID: 69949088383     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/635126     Document Type: Article

References (32)

1. Okolicsanyi L, Nassuato O, Muraca M, et al. Epidemiology of unconjugated hyperbilirubinemia: Revisited. Semin Liver Dis 1988;8:179-82.
2. Blanckourt N, Fevery J. Chapter 11: Physiology and pathophysiology of bilirubin metablism. In: D Zakim, TD Boyer, eds. Hepatology. A textbook of Liver Diseases, 2nd edn. Philadelphia: WB Saunders Company, 1990:282-5.
3. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11:669-74.
4. Melton IJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
5. Roullard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001;33:301-7.
6. Floreani A, Chiaramonte M, Giannini S, etal longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. J Hepatol 1991; 12:217-23.
7. Diamond TH, Stiel D, Lunzer M, McDowall D, Eckstein RP, Posen S. Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease. Gastroenterology 1989;96:213-21.
8. Bonkovsky HL, Hawkins M, Steinberg K, et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990;12;273-80.
9. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures liver diseas. Hepatology 1990;31-82-7
10. Masaki K, Shiomi S, Kuroki T, Tanaka T, Monna T, Ochi H. Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver. J Gastroenterol 1998;33:236-40.
11. Olsson R, Johansson C, Lindstedt G, Mellstrom. D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol 1994;29:753-6.
12. Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmue chronic active hepatitis on maintenance corticosteroid therapy Gastroenterology 1985;89:1078-83.
13. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990;31:82-7.
14. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs RL. Role of hyperbilrubinemia in the impairment of osteoblast prolifelation asipciated with cholestatic jaundice.
15. Tenenhouse A, Joseph L, Kreiger N, et al; CaMos Research Group. Canadian Mulucentre Osteoporosis Study. Estimation of the prevalence of low bone density in Canadian women and men using population-specific DXA reference standard: The Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000; 11:897-904.
16. Blake GM, Knapp KM, Spector TD, Fogelman I. Predicting she risk of fracture at any site in the skeleton: Are all boie mineral density measurement sites equally effective? Calcif Tissue Int 2006;78:9-17.
17. Clarke BL, Ebeling PR, Jones JD, et al. Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int 2002;70:137-45
18. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
19. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
20. Garnero P, Delmas PD. Bone Markers. Baillieres Clin Rheumatol 1997;11:517-37.
21. Garnero, P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49.
22. Midtby M, Magnus JH, Joakimsoen RM. The Tromso Study: A population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int 2001;12:835-43.
23. Lovisetto P, Giorcelli W, Actis GC, Biarese V. Gilbert's jaundice. Current clinico-nosographic, physiopathological and therapeutic aspects. III. Therapeutic action of enzyme inductors with reference to unconjugated bilirubin icterus. Minerva Med 1977;68:73-81.
24. Ellis E, Wagner M, Lammert F, et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J Hepatol 2006;44:243-5.
25. Hafkamp AM, Havinga R, Sinaasappel M, Verkade HJ. Effective oral treatment of unconjugated hyperbilirubinemia in Gunn rats. Hepatology 2005;41:526-34.
26. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 2004;150:179-87.
27. Goffin E, Devogelaer JP. Bone disorders after organ transplantation. Transplant Proc 2005;37:2832-3.
28. Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001;98:12671-6.
29. Orrick JJ, Steinhart CR. Atazanavir. Ann Pharmacother 2001;98:1664-74.
30. Prior J, Burdge D, Maan E, et al. Fragility fractures and bone mineral density in HIV positive women: A case-control population based density. Osteoporosis Int 2007;18:1345-53.
31. Bongiovanni M, Fausto A, Cicconi P. et al. Osteoporosis in HIV-infected subjects: A combined effect of highly active antiretroviral therapy and HIV-itself? J Acquir Immune Defic Syndr 2005;40:506-4.
32. Annapoorna N, Rao GV, Reddy NS, Rambabu R. Rao KR. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004;1:152-64.